Press Releases Year None201820172016 Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology December 4, 2018 PDF Version View HTML Gamida Cell Reports Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at ASH 2018 Annual Meeting December 3, 2018 PDF Version View HTML Gamida Cell to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference November 28, 2018 PDF Version View HTML Gamida Cell Announces New Translational Data for Nicord® to Be Presented at ASH 2018 Annual Meeting November 1, 2018 PDF Version View HTML Gamida Cell Announces Pricing of Initial Public Offering October 26, 2018 PDF Version View HTML Gamida Cell Strengthens Its Board of Directors with Appointment of Robert Blum as Chairman September 18, 2018 PDF Version View HTML Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications August 6, 2018 PDF Version View HTML Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access July 23, 2018 PDF Version View HTML Gamida Cell Receives Orphan Drug Designation from the FDA for NiCord® as a Treatment for Hematopoietic Stem Cell Transplantation July 17, 2018 PDF Version View HTML Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma June 18, 2018 PDF Version View HTML Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 17
